



Ymddiriedolaeth GIG  
Prifysgol Felindre  
Velindre University  
NHS Trust



Pencadlys Ymddiriedolaeth GIG Prifysgol Felindre  
Velindre University NHS Trust Headquarters  
2 Cwrt Charnwood  
Heol Billingsley  
Parc Nantgarw  
Caerdydd/Cardiff  
CF15 7QZ  
Ffôn/Phone : (029) 20196161  
<https://velindre.nhs.wales>

Date: 21<sup>st</sup> May 2024  
Ref: CORP 2024 - 093

Dear xxx

**Freedom of Information request: Treatment of cancers – electronic prescribing system (CORP 2024 – 093)**

Thank you for your request for information which the Trust received on 26<sup>th</sup> April 2024.

Your Request:

**Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2023 and end of December 2023?**

Name of medicine	Number patients treated
1.1 Abemaciclib (Verzenios)	
1.2 Alpelisib (Piqray)	
1.3 Fulvestrant (fulvestrant or Faslodex)	
1.4 Palbociclib (Ibrance)	
1.5 Ribociclib (Kisqali)	

**Q2. How many patients received abemaciclib (Verzenios) with the following treatment intent in the 3 months between the start of October 2023 and end of December 2023?**

Treatment intent	Number patients treated
2.1 Curative	
2.2 Palliative	
2.3 Not known / stated	


**Q3. How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the start of October 2023 and end of December 2023?**

Name of combination or monotherapy	Number patients treated
3.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)	
3.2 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)	
3.3 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)	

**PROSTATE CANCER**

**Q4. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2023 and end of December 2023?**

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.  
Velindre University NHS Trust is happy to receive communication in Welsh or English.



Name of medicine	Number patients treated
4.1 Abiraterone (Zytiga or generic abiraterone)	
4.2 Apalutamide (Erleada)	
4.3 Cabazitaxel (Jevtana or generic cabazitaxel)	
4.4 Darolutamide (Nubeqa)	
4.5 Enzalutamide (Xtandi)	

**Q5. How many patients were treated with docetaxel specifically for prostate cancer (ICD-10 code = C61) in the 3 months between the start of October 2023 and end of December 2023?**

Name of medicine	Number patients treated
Docetaxel	

**Q6. How many patients were treated with darolutamide in combination with docetaxel and / or androgen deprivation therapy in the 3 months between the start of October 2023 and end of December 2023?**

Name of medicine	Number patients treated
Darolutamide (Nubeqa) + Docetaxel + androgen deprivation therapy	

Please find the Trust's response below:

**Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2023 and end of December 2023?**

Name of medicine	Number patients treated
1.1 Abemaciclib (Verzenios)	12
1.2 Alpelisib (Piqray)	<6*
1.3 Fulvestrant (fulvestrant or Faslodex)	84
1.4 Palbociclib (Ibrance)	179
1.5 Ribociclib (Kisqali)	48

Data shows number of unique patients treated with the above, as such some of these patients may have received more than one of these drugs/treatments.

\*The Trust has a legal obligation to comply with the Data Protection Act 2018 and the retained EU GDPR 679/2016 (known as UK GDPR). As you have requested information about someone other than yourself, the Trust has applied an Absolute Exemption under Section 40(1) and (2)(a) of the Freedom of Information Act 2000 which states:

- (1) Any information to which a request for information relates is exempt information if it constitutes personal data of which the applicant is the data subject.
- (2) Any information to which a request for information relates is also exempt information if -
  - (a) it constitutes personal data which does not fall within subsection (1)

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.  
Velindre University NHS Trust is happy to receive communication in Welsh or English.

**Q2. How many patients received abemaciclib (Verzenios) with the following treatment intent in the 3 months between the start of October 2023 and end of December 2023?**

Treatment intent	Number patients treated
2.1 Curative	0
2.2 Palliative	11
2.3 Not known / stated	<6*

Data shows number of unique patients treated with the above, as such some of these patients may have received more than one of these drugs/treatments.

\*The Trust has a legal obligation to comply with the Data Protection Act 2018 and the retained EU GDPR 679/2016 (known as UK GDPR). As you have requested information about someone other than yourself, the Trust has applied an Absolute Exemption under Section 40(1) and (2)(a) of the Freedom of Information Act 2000 which states:

- (1) Any information to which a request for information relates is exempt information if it constitutes personal data of which the applicant is the data subject.
- (2) Any information to which a request for information relates is also exempt information if -
  - (a) it constitutes personal data which does not fall within subsection (1)

**Q3. How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the start of October 2023 and end of December 2023?**

Name of combination or monotherapy	Number patients treated
3.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)	12
3.2 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)	34
3.3 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)	<6*

Data shows number of unique patients treated with the above, as such some of these patients may have received more than one of these drugs/treatments.

\*The Trust has a legal obligation to comply with the Data Protection Act 2018 and the retained EU GDPR 679/2016 (known as UK GDPR). As you have requested information about someone other than yourself, the Trust has applied an Absolute Exemption under Section 40(1) and (2)(a) of the Freedom of Information Act 2000 which states:

- (1) Any information to which a request for information relates is exempt information if it constitutes personal data of which the applicant is the data subject.
- (2) Any information to which a request for information relates is also exempt information if -
  - (a) it constitutes personal data which does not fall within subsection (1)

**Q4. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2023 and end of December 2023?**

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.  
Velindre University NHS Trust is happy to receive communication in Welsh or English.

Name of medicine	Number patients treated
4.1 Abiraterone (Zytiga or generic abiraterone)	128
4.2 Apalutamide (Erleada)	27
4.3 Cabazitaxel (Jevtana or generic cabazitaxel)	14
4.4 Darolutamide (Nubeqa)	13
4.5 Enzalutamide (Xtandi)	38

Data shows number of unique patients treated with the above, as such some of these patients may have received more than one of these drugs/treatments.

**Q5. How many patients were treated with docetaxel specifically for prostate cancer (ICD-10 code = C61) in the 3 months between the start of October 2023 and end of December 2023?**

Name of medicine	Number patients treated
Docetaxel	49

Data shows number of unique patients treated with the above, as such some of these patients may have received more than one of these drugs/treatments.

**Q6. How many patients were treated with darolutamide in combination with docetaxel and / or androgen deprivation therapy in the 3 months between the start of October 2023 and end of December 2023?**

Name of medicine	Number patients treated
Darolutamide (Nubeqa) + Docetaxel + androgen deprivation therapy	8

Data shows number of unique patients treated with the above, as such some of these patients may have received more than one of these drugs/treatments.

I trust this answers your request for information, however, should you not be satisfied with the information supplied or the process of supplying it, you have a right to complain and request a review. Please note that you must submit a request for a review within 40 days of the date of this letter.

You should forward your complaint to:

Mr Ian Bevan via [FOI.VUNHST@wales.nhs.uk](mailto:FOI.VUNHST@wales.nhs.uk)  
Head of Information Governance  
Velindre University NHS Trust  
2, Charnwood Court  
Heol Billingsley  
Parc Nantgarw  
Cardiff / Caerdydd  
CF15 7QZ

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.  
Velindre University NHS Trust is happy to receive communication in Welsh or English.



Ymddiriedolaeth GIG  
Prifysgol Felindre  
Velindre University  
NHS Trust



Pencadlys Ymddiriedolaeth GIG Prifysgol Felindre  
Velindre University NHS Trust Headquarters  
2 Cwrt Charnwood  
Heol Billingsley  
Parc Nantgarw  
Caerdydd/Cardiff  
CF15 7QZ  
Ffôn/Phone : (029) 20196161  
<https://velindre.nhs.wales>

Should you wish to take your complaint further, if you are still unhappy with the decision after review, you can contact the:

Information Commissioner's Office - Wales  
2nd Floor,  
Churchill House,  
Churchill Way,  
Cardiff,  
CF10 2HH  
Telephone: 0330 414 6421  
email: [wales@ico.org.uk](mailto:wales@ico.org.uk)

Yours sincerely

**Lauren Fear**  
**Director of Corporate Governance and Chief of Staff**  
Velindre University NHS Trust  
2 Charnwood Court  
Heol Billingsley  
Parc Nantgarw  
Cardiff  
CF15 7QZ

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.  
Velindre University NHS Trust is happy to receive communication in Welsh or English.

